Immunotherapy waxay kaa caawin kartaa inaad ku guulaysato dagaalka ka dhanka ah Multiple Myeloma!

Immunotherapy waxay kaa caawin kartaa inaad ku guulaysato dagaalka lagula jiro Multiple Myeloma

La qaybso Post this

Soo ogow sida immunotherapy u noqon karto saaxiibkaaga dhabta ah ee garaaca myeloma! Boggeena wuxuu bixiyaa aragtiyo fudud oo ku saabsan awoodda tallaalka tallaalka ee myeloma badan. Ha ku seegin kheyraadkan si aad u awood badan, xog-ogaalnimo leh oo lagula dagaalamo myeloma. Waa furahaaga fahamka iyo wajahda dagaalka si kalsooni iyo rajo leh.

Welcome to a comprehensive exploration of “Immunotherapy for Multiple Myeloma” – which acts as a marvelous weapon against cancer.

Meelo badan, a type of blood cancer originating in plasma cells, presents unique challenges in traditional treatment approaches.

This blog is here to help you understand more about this kansarka dhiigga and introduce you to a new and promising treatment called immunotherapy.

Waxaan ku bilaabi doonaa inaan sharaxno waxa ay tahay dhowr myeloma, sida ay u saameyso dadka, iyo sida ay u horumartay daawaynta badan ee myeloma ee Hindiya ayaa isbedel weyn ku samaynaysa sida aan ula dagaalanno kansarka.

Immunotherapy is a superhero treatment, and today we’ll look at how it works and hear sheekooyin of people who have benefited from it.

Markaa nala kaalay markaan sahaminayo adduunka myeloma badan oo aan aragno sida tallaalka difaaca jirka uu rajo u siinayo oo uu isbeddello togan ugu keenayo habka aan u maareyno xaaladdan adag.

Immunotherapy ee Multiple Myeloma

Gudaha Dunida Kansarka Dhiiga: Waa maxay Myeloma Multiple?

Multiple myeloma waa nooc kansar ah oo ka bilaabma dhiiggaaga. Waxay dhacdaa marka qaar ka mid ah unugyada gaarka ah ee loo yaqaanno unugyada plasma ay ku guul daraysteen inay si habboon u shaqeeyaan.

Caadiyan, unugyada balasaska waxay jidhkaaga ka caawiyaan la dagaalanka jeermiska iyagoo samaynaya unugyada difaaca jirka. Laakiin myeloma badan, unugyadan dhibka keenaya waxay ku dhismaan lafahaaga waxayna keenaan dhibaatooyin.

Unugyadan waxyeellada leh waxay galaan meel bannaan oo dhuuxa lafta ah, taas oo ah gudaha jilicsan ee lafahaaga halkaasoo unugyada dhiigga laga soo saaro.

Waxay iska fogeeyaan unugyada wanaagsan, halkii ay ka soo saari lahaayeen unugyada difaaca jirka, waxay soo saaraan borotiinno aan si sax ah u shaqeyn. Tani waxay sababtaa myeloma badan waxayna kaa dhigaysaa caafimaad darro.

Immunotherapy ee Multiple Myeloma

Sidee ayay Multiple Myeloma u saameeyaa fayoobidaada?

Myeloma-da badan waxay si weyn u saameyn kartaa wanaaggaaga siyaabo kala duwan. Waa kuwan dulmar ku saabsan sida kansarku kuu saameyn karo:

Lafo Xanuun iyo Jab

Nidaamka Difaaca Jilicsan

Daal

Anemia

Arrimaha Kelyaha

Arimaha Nidaamka Dareenka

Saamaynta Caafimaadka Maskaxda

Waa maxay Immunotherapy?

Immunotherapy waa daaweyn kansar oo cajiib ah oo adeegsata habka difaaca jirka si uu u raadiyo oo u burburiyo unugyada kansarka. Nidaamka difaacaagu waxa uu awood u leeyahay in uu ogaado oo ka saaro kuwa soo gala sida kansarka.

Immunotherapy for myeloma waxay u shaqeysaa sida tallaalka xoojinta, taasoo kor u qaadeysa awoodda habka difaaca jirka si uu u ogaado oo u burburiyo unugga myeloma. Noocan daaweynta kansarka ayaa la xaqiijiyay waxtarka weyn, oo u ballan qaaday nolol dheer oo bukaanno badan oo kansar ah.

Intaa waxaa dheer, horumarka hadda jira ee cilmi-baarista caafimaadku waxay sii wadaan soo bandhigida daawaynta cusub ee immunotherapy sida - daawaynta unugyada baabuurka t ee Hindiya.

Marka la soo koobo, immunotherapy waxay la mid tahay xoojinta difaacaada dabiiciga ah, taasoo ka caawinaysa jirkaaga inuu si caqli badan oo awood leh ula dagaallamo cudurrada halista ah.

Immunotherapy ee Multiple Myeloma

Waa maxay Noocyada Immunotherapy ee Multiple Myeloma?

Daaweynta Unug ee CAR-T:

CAR T-cell therapy waa daawaynta immunotherapy multi-myeloma ee shakhsi ahaaneed oo ay ku jirto soo saarida unugyada T ee bukaanka (nooc ka mid ah unugyada difaaca), iyaga oo wax ka beddelaya shaybaar si ay u muujiyaan unugga antigen-ka ee si door ah u bartilmaameedsada unugyada kansarka, ka dibna dib u soo celinta iyaga. dib ugu noqo bukaanka.

Akhbaarta wanaagsan ayaa ah in Qiimaha daawaynta unugyada CAR T ee Hindiya way ka yar tahay marka loo eego umadaha kale ee aduunka. Laba ikhtiyaar oo ah tallaalka difaaca unugga t unug ee baabuurka ee loogu talagalay myeloma badan ayaa waxaa horey u ansixisay FDA.

Wakiilada Immunomodulatory:

Daawooyinkan immunotherapy ee badan waa qayb muhiim ah oo ka mid ah daawaynta myeloma badan, waxayna u shaqeeyaan iyagoo wax ka beddelaya jawaabta difaaca jirka.

Daawooyinkani maaha oo kaliya inay si toos ah u beegsadaan unugyada kansarka laakiin sidoo kale waxay saameeyaan microenvironment ku hareeraysan si ay uga dhigaan mid aan martigelinin koritaanka unugyada myeloma.

Daawooyinkani waxay caawiyaan inay xaddidaan horumarka myeloma badan waxayna wanaajiyaan natiijooyinka guud ee daaweynta iyagoo saameynaya jawaabta difaaca.

Haddii myeloma qofka uu soo noqnoqdo ama uusan si fiican uga falcelin daawaynta kale, daawooyinkani waxay weli noqon karaan kuwo faa'iido leh.

Kahortagga Isbaarada:

Kahortagga isbaarada waa nooc ka mid ah daaweynta difaaca jirka oo ka shaqeysa xannibista borotiinnada qaarkood oogada unugyada difaaca jirka ama unugyada kansarka. Kahortagayaasha isbaarada waxay u shaqeeyaan sidii hab-dhiska difaaca ee ilaalinta taraafikada.

Waxay xannibi karaan calaamadaha hoos u dhigaya jawaabcelinta difaaca jirkeena ama waxay kicin karaan calaamadaha xoojiya.

Tani waxay u ogolaaneysaa jirkeena inuu si fiican u beegsado oo uu weeraro unugyo badan oo myeloma ah iyadoo la ilaalinayo unugyada caafimaadka qaba. Saynis yahanadu waxay ku tijaabinayaan horjoogayaashan tijaabooyinka difaaca jirka ee myeloma badan, iyo natiijooyinka hore waxay muujinayaan inay hayaan ballanqaadyo badan.  

Unugyada difaaca jirka ee monoclonal:

Unugyada difaaca jirka ee monoclonal waa unugyo shaybaar lagu sameeyay oo ku celceliya habka difaaca jirka si uu isaga difaaco fayrasyada iyo bakteeriyada waxyeelada leh. Saynis yahanadu waxay ogaadeen sida loo sameeyo unugyada difaaca jirka ee shaybaadhka.

Unugyada difaaca jirka ee shaybaadhka sameeyay waxay hagaajin karaan difaacyadayada dabiiciga ah, iyaga oo u oggolaanaya inay si fiican u bartilmaameedsadaan oo ay weeraraan unugyada myeloma. Daawayntan myeloma-da badan waxay caawisaa dhimista tirada unugyada kansarka iyo xakamaynta horumarka cudurka.

Saamaynta Wanaagsan ee Immunotherapy ee Nolosha

Immunotherapy ee myeloma waxay keenaysaa rajo cusub nolosha bukaanno badan. Aynu aragno qaar ka mid ah faa'iidooyinkeeda ugu waaweyn -

Immunotherapy waxay hagaajin kartaa awoodda jidhka si loo aqoonsado oo loo burburiyo unugyada kansarka, hagaajinta waxtarka daaweynta.

Immunotherapy waxay inta badan keentaa waxyeelooyin yar yar marka loo eego daawaynta caadiga ah sida kiimoterabiga.

Daaweynta difaaca jirka, bukaannada qaarkood waxay leeyihiin cafis waara ama xitaa soo kabasho buuxda, taasoo bixisa rajo nolol dheer oo caafimaad leh.

Immunotherapy waxay hagaajinaysaa caafimaadka guud ee bukaanka iyo tayada nolosha bukaanka kansarka iyadoo yaraynaysa darnaanta waxyeelada.

Immunotherapy ee Multiple Myeloma

Sidee Immunotherapy Dib Ugu Qortay Sheekada Nololeed Ee Ka Badbaadiyaha Kansarka?

Bjørn Simonsen, oo 67 jir ah, waxa uu la kulmay safar adag oo leh myeloma badan. Ka dib wareegii koowaad ee kiimoterabiga, soo noqoshada 2021 waxay keentay daawaynta aan lagu guulaysan.

Wuxuu aaday Isbitaalka Lu Daopei bishii Febraayo 2022 si uu u helo daawaynta unugyada CART. Ka dib diyaarinta fludarabine iyo cyclophosphamide, unugyada CART ayaa la duray.

Inkastoo uu lahaa qandho neutropenia, xiniinyaha midig wuxuu si tartiib tartiib ah ugu soo noqday caadi. Maalintii 28-aad, tijaabooyinka dhuuxa lafta ma soo bandhigin unugyo balaasma ah oo la ogaan karo.

Mr. Simensen ayaa la sii daayay iyada oo ballamaha daba-galka ah loo qorsheeyay, waayo-aragnimadiisuna waxay muujinaysaa sida daaweynta unugyada CART loo isticmaali karo in lagu daweeyo bukaannada soo noqnoqda iyo dib-u-celinta myeloma badan.

Sheekadan guusha badan ee difaaca jirka ee myeloma waxay ina baraysaa qiimaha go'aan adag, fikirka togan, iyo awooda daawaynta kansarka ee horumarka leh.

Afkaarta Final

Markaad la kulanto caqabada myeloma, xusuusnow tan: Waxaad tahay sida askari geesi ah oo dagaalka nolosha ah. Xitaa marka arrimuhu u muuqdaan kuwo adag, dariiqa cusub ee daawaynta difaaca jirka ee myeloma badan ayaa halkan u jooga si ay u caawiyaan.

Waa habka saxda ah ee safarkaaga ka hortagga badbaadada kansarka. Markaa, sii wad, oo daawayntan ha kuu horseedo nolol caafimaad leh oo farxad leh.

Haddii aad hayso wax su'aalo ah oo ku saabsan daaweyntan, xor ayaad u tahay inaad na soo wacdo wakhti kasta. Waxaan kugula xiriirin karnaa machadka ugu fiican ee kansarka kaas oo bixiya daawaynta difaaca jirka ee ugu horumarsan.

Ku soo Dhawo Wargeyskayaga

Hel wax cusub oo waligaa ha ka maqnaan blog ka Cancerfax

Inbadan Oo La Baadho

Lutetium Lu 177 dotatate waxa ansixisay USFDA bukaanada carruurta 12 sano iyo ka weyn ee GEP-NETS
Kansarka

Lutetium Lu 177 dotatate waxa ansixisay USFDA bukaanada carruurta 12 sano iyo ka weyn ee GEP-NETS

Lutetium Lu 177 dotatate, oo ah daawayn hor leh, ayaa dhawaan ogolaansho ka heshay Maamulka Cunnada iyo Dawooyinka ee Maraykanka (FDA) ee bukaanada carruurta, taas oo calaamad u ah guul muhiim ah oo ku saabsan kansarka carruurta. Oggolaanshahani waxa uu u taagan yahay iftiin rajo u ah carruurta la dagaallamaysa burooyinka neuroendocrine (NETs), oo ah nooc naadir ah laakiin adag oo kansar ah kaas oo inta badan caddeeya u adkaysiga daaweynta caadiga ah.

Nogapendekin alfa inbakicept-pmln waxa u ansixisay USFDA kansarka kaadiheysta ee aan muruqa ahayn ee aan ka jawaabin BCG
Kansarka kaadiheysta

Nogapendekin alfa inbakicept-pmln waxa u ansixisay USFDA kansarka kaadiheysta ee aan muruqa ahayn ee aan ka jawaabin BCG

"Nogapendekin Alfa Inbakicept-PMLN, immunotherapy novel, waxay muujinaysaa ballanqaad daawaynta kansarka kaadiheysta marka lagu daro daawaynta BCG. Habkan cusubi waxa uu bartilmaameedsanayaa calaamado gaar ah oo kansar ah iyada oo la xoojinayo jawaabta habka difaaca jidhka, iyada oo kor u qaadeysa waxtarka daaweynta dhaqameed sida BCG. Tijaabooyin caafimaad ayaa muujinaya natiijooyin dhiirigelin leh, oo muujinaya natiijooyinka bukaan-socodka oo soo hagaagay iyo horumarka suurtagalka ah ee maareynta kansarka kaadiheysta. Is-waafajinta ka dhexeeya Nogapendekin Alfa Inbakicept-PMLN iyo BCG waxay ku bishaaraynaysaa waa cusub oo daawaynta kansarka kaadiheysta."

Ma u baahan tahay caawimaad? Kooxdayadu waxay diyaar u yihiin inay ku caawiyaan.

Waxaan u rajeynaynaa caafimaad deg-deg ah mid aad jeceshahay iyo mid kuu dhow.

Bilow sheekada
Waxaan nahay Online! Nala hadal!
Sawir koodka
Hello,

Ku soo dhawoow CancerFax!

CancerFax waa madal horudhac ah oo u heellan in lagu xidho shakhsiyaadka wajahaya kansarka heerka sare ee daawaynta unugyada sida CAR T-Cell therapy, daawaynta TIL, iyo tijaabooyinka caafimaad ee adduunka oo dhan.

Nala soo socodsii waxaan kuu qaban karno.

1) Daaweynta kansarka ee dibadda?
2) CAR T-Cell therapy
3) Tallaalka kansarka
4) La-talinta fiidiyowga ee khadka tooska ah
5) daawaynta Proton